


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	1	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
B1	2,635,978		04-21-1953	Massengale	
B2	2,954,314		09-27-1960	Metzger, et al.	
B3	3,309,373		03-14-1967	Danzig	
B4	4,954,526		09-04-1990	Keefer	
B5	5,039,705		08-13-1991	Keefer, et al.	
B6	5,155,137 A		10-13-1992	Keefer, et al.	
B7	5,208,233 A		05-04-1993	Keefer, et al.	
B8	5,212,204		05-18-1993	Keefer, et al.	
B9	5,250,550		10-05-1993	Keefer et al.	
B10	5,366,997		11-22-1994	Keefer et al.	
B11	5,374,710		12-20-1994	Tsien et al.	
B12	5,389,675		02-14-1995	Christodoulou et al.	
B13 **	5,405,919		04-11-1995	Keefer et al.	
B14	5,482,925		01-09-1996	Hutsell	
B15	5,519,020		05-21-1996	Smith, et al.	
B16 **	5,525,357		06-11-1996	Keefer et al.	
B17	5,536,723 A		07-16-1996	Loscalzo, et al.	
B18	5,574,068 A		11-12-1996	Stamler, et al.	
B19 **	5,632,981		05-27-1997	Saavedra et al.	
B20	5,650,442		07-22-1997	Mitchell, et al.	
B21	5,650,447		07-22-1997	Keefer et al.	
B22 **	5,665,077		09-09-1997	Rosen et al.	
B23 **	5,676,963		10-14-1997	Keefer et al.	
B24	5,683,668		11-04-1997	Hrabie et al.	
B25 **	5,691,423		11-25-1997	Smith et al.	
B26	5,698,738		12-16-1997	Garfield, et al.	
B27	5,700,830		12-23-1997	Korthuis et al.	
B28	5,714,511		02-03-1998	Saavedra et al.	
B29 **	5,718,892		02-17-1998	Keefer et al.	
B30	5,721,365		02-24-1998	Keefer et al.	
B31	5,731,305		03-24-1998	Keefer et al.	
B32 **	5,770,645		06-23-1998	Stamler, et al.	
B33	5,789,447		08-04-1998	Wink, Jr. et al.	
B34 **	5,811,121 A		09-22-1998	Wu, et al.	
B35	5,814,656		09-29-1998	Saavedra et al.	
B36	5,814,666		09-29-1998	Green et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Date Submitted: October 12, 2007

(use as many sheets as necessary)

Complete if Known

Application Number	10/588,718
Filing Date	01/06/2005
First Named Inventor	Ernst V. ARNOLD
Art Unit	1616
Examiner Name	Unassigned

Sheet 2 of 15 Attorney Docket Number 065611-0119**U.S. PATENT DOCUMENTS**

	Document Number		
B37 xx	5,827,741	10-27-1998	Beattie, et al.
B38	5,837,736	11-17-1998	Mitchell et al.
B39	5,840,759	11-24-1998	Mitchell, et al.
B40	5,910,316	06-08-1999	Keefer, et al.
B41	5,958,427	09-28-1999	Salzman et al.
B42 xx	5,962,520	10-05-1999	Smith et al.
B43	6,110,453	08-29-2000	Keefer et al.
B44	6,147,068	11-14-2000	Smith et al.
B45 xx	6,200,558 B1	03-13-2001	Saaverdra et al.
B46	6,218,016 B1	04-17-2001	Tedeschi, et al.
B47 xx	6,232,336	05-15-2001	Hrabie, et al.
B48 xx	6,232,434 B1	05-15-2001	Stamler, et al.
B49	6,261,594 B1	07-17-2001	Smith et al.
B50 xx	6,270,779	08-07-2001	Fitzhugh et al.
B51	6,290,981	09-18-2001	Keefer, et al.
B52 xx	6,359,182 B1	03-19-2002	Stamler, et al.
B53	6,379,660	04-30-2002	Saavedra, et al.
B54	6,410,622 B1	06-25-2002	Endres
B55	6,451,337 B1	09-17-2002	Smith et al.
B56 xx	6,511,991 B2	01-28-2003	Hrabie, et al.
B57 xx	6,576,258 B1	06-10-2003	Kofler, et al.
B58	6,610,660 B1	08-26-2003	Saavedra, et al.
B59	6,673,891 B2	01-06-2004	Stamler et al.
B60 xx	6,703,046 B2	03-09-2004	Fitzhugh et al.
B61	6,706,274 B2	03-16-2004	Herrmann et al.
B62	6,737,447 B1	05-18-2004	Smith et al.
B63	6,750,254 B2	06-15-2004	Hrabie et al.
B64	6,855,366 B2	02-15-2005	Smith et al.
B65	6,911,433 B2	06-28-2005	Saavedra et al.
B66	6,911,478 B2	06-28-2005	Hrabie et al.
B67	6,949,530 B2	09-27-2005	Hrabie et al.
B68	6,951,902 B2	10-04-2005	McDonald et al.
B69	7,105,502 B2	09-12-2006	Arnold et al.
B70	7,122,529 B2	10-17-2006	Ruane et al.
B71	7,135,189 B2	11-14-2006	Knapp
B72	7,169,404 B2	01-30-2007	Hossainy et al.
B73	2003/0147845 A1	08/07/2003	Saavedra, et al.
B74	2005/0203069	09-15-2005	Arnold, et al.
B75	2006/0008529 A1	01-12-2006	Meyerhoff et al.

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>October 12, 2007</u> (use as many sheets as necessary)				Complete if Known	
Sheet	3	of	15	Application Number	10/588,718
				Filing Date	01/06/2005
				First Named Inventor	Ernst V. ARNOLD
				Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

U.S. PATENT DOCUMENTS

		Document Number			
	B76	2007/0196327 A1	08/23/2007	Kalivretenos et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
B77		WO 95/12394	05-11-1995	The United States of America		
B78		WO 95/24908	09-21-1995	The United States of America		
B79		WO 96/15781	05-30-1996	The United States of America		
B80		WO 96/15797	05-30-1996	The United States of America		
B81		WO 96/32136	10-17-1996	The United States of America		
B82		WO 98/19996	05-14-1998	Children's Hospital Medical Center		
B83		WO 99/01427	01-14-1999	The Government of the United States of America		
B84		WO 99/33823	07-08-1999	Nycomed Imaging AS		
B85		WO 01/26702 A2	04-19-2001	The University of Akron		
B86		WO 01/85227 A2	11-15-2001	Medtronic Ave		
B87		WO 02/41902 A1	05-30-2002	The University of Akron		
B88		WO 2005/039664 A2	05-06-2005	Cube Medical A/S		
B89		WO 2005/081752 A2	09/09/2005	Amulet Pharmaceuticals, Inc.		
B90		WO 2005/081753 A3	09-09-2005	Noxilizer, Inc.		
B91		WO 2006/037105 A2	04-06-2006	Government of the United States of America		
B92		WO 2006/064056 A2	06-22-2006	NOLabs AB		
B93		WO 2006/084909 A1	08-17-2006	NOLabs AB		
B94		WO 2006/084910 A2	08-17-2006	NOLabs AB		
B95		WO 2006/084911 A2	08-17-2006	NOLabs AB		
B96		WO 2006/084912 A1	08-17-2006	NOLabs AB		
B97		WO 2006/084913 A2	08-17-2006	NOLabs AB		
B98		WO 2006/100154 A1	09-28-2006	NOLabs AB		
B99		WO 2006/125016 A1	11-23-2006	The Governors of the University of Alberta		
B100		WO 2006/128121 A2	11/30/2006	The University of North Carolina at Chapel Hill		
B101		WO 2007/067477 A1	06-14-2007	The University of North Carolina at Chapel Hill		

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	4	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B102 xx	AHMADE et al., "Suberimidate Crosslinking Shows that a Rod-shaped, Low Cystine, High Helix Protein Prepared by Limited Proteolysis of Reduced Wool has Four Protein Chains," <u>FEBS Letters</u> , Oct. 1978, Vol. 94, No. 2, pp. 365-367, Elsevier/North-Holland Biomedical Press.	
	B103 xx	AL-SA'DONI et al., "Neocuproine, a Selective Cu(I) Chelator, and the Relaxation of Rat Vascular Smooth Muscle by S-nitrosothiols," <u>British J. of Pharm.</u> , 1997, Vol. 121, pp. 1047-1050, Stockton Press.	
	B104	ANASTASIOU et al., "Aminosalicylate-Based Biodegradable Polymers: Syntheses and <i>in vitro</i> Characterization of Poly(anhydride-ester)s and Poly(anhydride-amide)s," <u>J. of Polymer Science: Part A: Polymer Chemistry</u> , 2003, Vol. 41, pp. 3667-3679, Wiley Periodicals, Inc.	
	B105 xx	ANNICH et al., "Reduced Platelet Activation and Thrombosis in Extracorporeal Circuits Coated with Nitric Oxide Release Polymers," <u>Crit. Care Med.</u> , 2000, Vol. 28, No. 4, pp. 915-920.	
	B106	ARNOLD et al., "Mechanistic Insight into Exclusive Nitric Oxide Recovery from a Carbon-bound Diazeniumdiolate," <u>Nitric Oxide</u> , 2002, Vol. 7, pp. 103-108, Academic Press.	
	B107	ARNOLD et al., "A Nitric Oxide-Releasing Polydiazeniumdiolate Derived from Acetonitrile," <u>Org. Lett.</u> , 2002, Vol. 4, No. 8, pp. 1323-1325, American Chemical Society.	
	B108	ARNOLD et al., "Reaction of Nitric Oxide with Benzyl Cyanide to Yield a Bis-diazeniumdiolated Imidate," <u>Tetrahedron Lett.</u> , 2000, Vol. 41, pp. 8421-8424, Elsevier Science Ltd.	
	B109	ARNOLD et al., "Surprising Reactivity of C-based Diazeniumdiolats: Conversion of a Nitrile to an Imidate and its Decomposition to Yield Nitric Oxide," (#111.) <u>Abstracts of Papers</u> , Part 1, 220 th ACS National Meeting, Aug. 20-24, 2000, Washington, D.C., American Chemical Society.	
	B110	ARULSAMY et al., "Dipotassium Ethane-1,1-diylbis(diazeniumdiolate) Monohydrate," <u>Acta Cryst.</u> , 2005, Section E61, pp m764-m766.	
	B111	ARULSAMY et al., "Disodium 3-oxobutane-2,2-diylbis-(diazeniumdiolate) Dihydrate," <u>Acta Cryst.</u> , 2005, Section E61, pp m838-m840.	
	B112	ARULSAMY et al., "Disodium 4-hydroxybutane-1,1-diylbis-(diazeniumdiolate) Sesquihydrate," <u>Acta Cryst.</u> , 2005, Section E61, pp m961-m963.	
	B113	ARULSAMY et al., "Multiplicity Control in the Polygeminal Diazeniumdiolation of Active Hydrogen Bearing Carbons: Chemistry of a New type of Trianionic Molecular Propeller," <u>J. Am. Chem. Soc.</u> , 2001, Vol. 123, No. 44, pp. 10860-10869, American Chemical Society.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	5	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B114	ARULSAMY et al., "New Methanetrisdiazoniumdiolates," <u>Tetrahedron Lett.</u> , 2003, Vol. 44, pp. 4267-4269, Elsevier Science Ltd.	
	B115	ARULSAMY et al., "Synthesis of Diazoniumdiolates from the Reactions of Nitric Oxide with Enolates," <u>J. Org. Chem.</u> , 2006, Vol. 71, No. 2, pp. 572-581, American Chemical Society.	
	B116	ARULSAMY et al., "Traube's 'Oxazomalonic Acid' is a 3-Hydroxysyndnone Carboxylate with an E-ONNO Geometry," <u>Angew. Chem. Int. Ed.</u> , 2002, Vol. 41, No. 12, pp. 2089-2091, Germany.	
	B117	ARULSAMY et al., "Tripotassium Carboxylatomethylenebis(diazonium-diolate) 2.5-Hydrate," <u>Acta Cryst.</u> , 2005, Section E61, pp. m930-m932.	
	B118 xx	ASKEW et al., "Chemical Mechanisms Underlying the Vasodilator and Platelet Anti-Aggregating properties of S-Nitroso-N-acetyl-DL-penicillamine and S-Nitrosoglutathione," <u>Bioorganic & Medicinal Chem.</u> , 1995, Vol. 3, No. 1, pp. 1-9, Elsevier Science Ltd., Great Britain.	
	B119 xx	AUSPRUNK et al., "Migration and Proliferation of Endothelial Cells in Preformed and Newly Formed Blood Vessels During Tumor Angiogenesis," <u>Microvascular Research</u> , 1977, Vol. 14, pp. 53-65, Academic Press Inc., Great Britain.	
	B120 xx	BARRETT et al., "Role of Calcium in Angiotensin II-Mediated Aldosterone Secretion," <u>Endocrine Reviews</u> , Nov. 1989, Vol. 10, No. 4, pp. 496-518, The Endocrine Society, U.S.A.	
	B121	BHAT et al., "N-Nitroso-N, O-dialkylhydroxylamines: preparation, structure, reaction," <u>J. Chem. Soc., Perkin Trans. 2</u> , 2000, pp. 1435-1446, The Royal Society of Chemistry.	
	B122 xx	BIERBAUM et al., "Growth of Self-Assembled n-Alkyltrichlorosilane Films on Si(100) Investigated by Atomic Force Microscopy," <u>Langmuir</u> , 1995, Vol. 11, No. 6, pp. 2143-2150, American Chemical Society.	
	B123	BOHLE et al., "Cyclohexadienone Diazoniumdiolates from Nitric Oxide Addition," <u>J. Org. Chem.</u> , 2000, Vol. 65, No. 18, pp. 5685-5692, American Chemical Society.	
	B124	BONIFANT et al., "Design and Synthesis of Arylated Diazoniumdiolates with Anti-leukemic Activity," (#292.), <u>Abstracts of Papers, Part 2, 221st ACS National Meeting</u> , Apr. 1-5, 2001, San Diego, CA, American Chemical Society.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	6	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B125	CARRE et al., "Convenient Preparation of Functionalised Polymer-Based Resins via an Economical Preparation of Chloromethylated Polystyrene Resins (Merrifield Type)," <u>Org. Process Research & Development</u> , 2000, Vol. 4, No. 6, pp. 606-610, American Chemical Society and The Royal Society of Chemistry.	
	B126	CHARVILLE et al., "Reduced <i>Escherichia Coli</i> and <i>Staphylococcus Aureus</i> Adhesion via Xerogel-derived Nitric Oxide Release," PMSE 410, <u>Joint PMSE/POLY Poster Session</u> , The 232nd ACS National Meeting, Sep. 10-14, 2006, San Francisco, CA, (file://D:\232ND\PMSE\P1005084.HTM).	
	B127 xx	CHERNOFF et al., "The Cellular and Molecular Basis of the Platelet Storage Lesion: a Symposium Summary," <u>Transfusion</u> , 1992, Vol. 32, No. 4, pp. 386-390.	
	B128	DAVIES et al., "Diazeniumdiolate Prodrug Activation in Model Membrane Systems," INOR 138, , The 232nd ACS National Meeting, Sep. 10-14, 2006, San Francisco, CA, (file://D:\232ND\INOR\P984797.HTM).	
	B129 xx	DE GROOTE et al., "NO Inhibitions: Antimicrobial Properties of Nitric Oxide," <u>CID</u> , 1995, Vol. 21 (Suppl 2), pp. S162-S165.	
	B130	DeROSA et al., "Nitric Oxide-Releasing Polymeric Materials Derived in Part From Acrylonitrile Monomer," (#247.) <u>Abstracts of Papers</u> , Part 2, 229 th ACS National Meeting, March 13-17, 2005, San Diego, CA, American Chemical Society.	
	B131 xx	DICKS et al., "Generation of Nitric Oxide from S-nitrosothiols using Protein-bound Cu ²⁺ Sources," <u>Chemistry & Biology</u> , 1996, Vol. 3, No. 8, pp. 655-659.	
	B132	DOBMEIER et al., "Nitric Oxide-Releasing Xerogel-Based Fiber-Optic pH Sensors," <u>Anal. Chem.</u> , Nov. 1, 2006, Vol. 78, No. 21, pp. 7461-7466.	
	B133 xx	ENDO K., "Chemical Modification of Metallic Implant Surfaces with Biofunctional Proteins (Part 1) Molecular Structure and Biological Activity of a Modified NiTi Alloy Surface," <u>Dental Materials J.</u> , 1995, Vol. 14, No. 2, pp. 185-198, Chemicon International Inc., Temecula (CA), Japan.	
	B134 xx	ESPEY et al., "A Chemical Perspective on the Interplay Between NO, Reactive Oxygen Species, and Reactive Nitrogen Oxide Species," <u>Ann. N.Y. Acad. Sci.</u> , 2002, Vol. 962, pp. 195-206, New York Academy of Sciences.	
	B135 xx	FERDINANDY et al., "Nitric Oxide, Superoxide, and Peroxynitrite in Myocardial Ischaemia-Reperfusion Injury and Preconditioning," <u>British J. of Pharm.</u> , 2003, Vol. 138, No. 4, pp. 532-543, Nature Publishing Group.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	7	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	B136	FLESER et al., "Nitric Oxide-Releasing Biopolymers Inhibit Thrombus Formation in a Sheep Model of Arteriovenous Bridge Grafts," <u>J. of Vascular Surgery</u> , Oct. 2004, Vol. 40, No. 4, pp. 803-811, The Society for Vascular Surgery.			
	B137 **	FREEDMAN et al., "Glutathione Peroxidase Potentiates the Inhibition of Platelet Function by S-Nitrosothiols," <u>J. Clin. Invest.</u> , July 1995, Vol. 96, pp. 394-400, The American Society for Clinical Investigation, Inc.			
	B138 **	GORDGE et al., "Role of a Copper (I)-Dependent Enzyme in the Anti-platelet Action of S-nitrosoglutathione," <u>British J. of Pharm.</u> , 1996, Vol. 119, pp. 533-538, Stockton Press.			
	B139	HOMER et al., "Cyclic GMP-Independent Relaxation of Rat Pulmonary Artery by Spermine NONOate, a Diazeniumdiolate Nitric Oxide Donor," <u>British J. of Pharm.</u> , 2000, Vol. 131, pp. 673-682, Macmillan Publishers Ltd.			
	B140	HRABIE et al., "Carbon-Bound Diazeniumdiolates from the Reaction of Nitric Oxide with Amidines," <u>J. Org. Chem.</u> , 2005, Vol. 70, No. 19, pp. 7647-7653, American Chemical Society.			
	B141	HRABIE et al., "Chemistry of the Nitric Oxide-Releasing Diazeniumdiolate ("Nitrosohydroxylamine") Functional Group and Its Oxygen-Substituted Derivatives," <u>Chem. Rev.</u> , 2002, Vol. 102, No. 4, pp. 1135-1154, American Chemical Society.			
	B142	HRABIE et al., "Conversion of Proteins to Diazeniumdiolate-Based Nitric Oxide Donors," <u>Bioconjugate Chem.</u> , 1999, Vol. 10, No. 5, pp. 838-842, American Chemical Society.			
	B143	HRABIE et al., "New Nitric Oxide-Releasing Zwitterions Derived from Polyamines," <u>J. Org. Chem.</u> , 1993, Vol. 58, No. 6, pp. 1472-1476, American Chemical Society.			
	B144 **	HRABIE et al., "Reaction of Nitric Oxide at the β-Carbon of Enamines. A New Method of Preparing Compounds Containing the Diazeniumdiolate Functional Group," <u>J. Org. Chem.</u> , 2000, Vol. 65, No. 18, pp. 5745-5751, American Chemical Society.			
	B145 **	JOURD'HEUIL et al., "Effect of Superoxide Dismutase on the Stability of S-Nitrosothiols," <u>Archives of Biochemistry and Biophysics</u> , Jan. 15, 1999, Vol. 361, No. 2, pp. 323-330, Academic Press.			
	B146 **	JOURD'HEUIL et al., "Nitric Oxide and the Gut," (Small Intestine), <u>Current Gastroenterology Reports</u> , 1999, Vol. 1, pp. 384-388, Current Science Inc. (ISSN 1522-8037).			
	B147	JUN et al., "Nitric Oxide-Producing Polyurethanes," <u>Biomacromolecules</u> , 2005, Vol. 6, No. 2, pp. 838-844, American Chemical Society.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	8	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B148 xx	KADER et al., "eNOS-Overexpressing Endothelial Cells Inhibit Platelet Aggregation and Smooth Muscle Cell Proliferation <i>in Vitro</i> ," <u>Tissue Engineering</u> , 2000, Vol. 6, No. 3, p. 241-251, Mary Ann Liebert, Inc.	
	B149	KANO et al., " <i>N</i> -Nitrosohydroxylamines. 2. Thermal Decomposition of <i>N,O</i> -Dibenzyl- <i>N</i> -nitrosohydroxylamines," <u>J. Org. Chem.</u> , 1993, Vol. 58, No. 6, pp. 1564-1567, American Chemical Society.	
	B150	KATRITZKY et al., "Utilization of Pyridinium Salts as Microsensor Coatings," <u>Langmuir</u> , 1989, Vol. 5, pp. 1087-1092, American Chemical Society.	
	B151	KAUL et al., "Polymeric-Based Perivascular Delivery of a Nitric Oxide Donor Inhibits Intimal Thickening After Balloon Denudation Arterial Injury: Role of Nuclear Factor-kappaB," <u>JACC</u> , Feb. 2000, Vol. 35, No. 2, pp. 493-501, Elsevier Science Inc.	
	B152	KEEFER et al., "Chemistry of the Diazeniumdiolates," <u>Nitric Oxide: Biology and Chemistry</u> , 2001, Vol. 5, No. 4, pp. 377-394.	
	B153	KEEFER L., "Nitric Oxide (NO)- and Nitroxyl (HNO)-Generating Diazeniumdiolates (NONOates): Emerging Commercial Opportunities," <u>Current Topics in Medicinal Chemistry</u> , 2005, Vol. 5, No. 7, pp. 625-636, Bentham Science Publishers Ltd.	
	B154	KEEFER L., "Progress Toward Clinical Application of the Nitric Oxide-Releasing Diazeniumdiolates," <u>Annu. Rev. Pharmacol. Toxicol.</u> , 2003, (plus figures and table of contents), Vol. 43, pp. 585-607.	
	B155	KERN et al., "Durability of Resin Bonds to Pure Titanium," <u>J. of Prosthodontics</u> , Mar. 1995, Vol. 4, No. 1, pp. 16-22, American College of Prosthodontists.	
	B156 xx	KLINGER M., "The Storage Lesion of Platelets: Ultrastructural and Functional Aspects," <u>Ann. Hematol.</u> , 1996, Vol. 73, pp. 103-112, Springer-Verlag.	
	B157 xx	KOWALUK et al., "Metabolic Activation of Sodium Nitroprusside to Nitric Oxide in Vascular Smooth Muscle," <u>J. of Pharmacology and Experimental Therapeutics</u> , 1992, Vol. 262, No. 3, pp. 916-922, American Society for Pharmacology and Experimental Therapeutics, U.S.A.	
	B158	LeROY et al., "A Method for Studying Small Intestinal Transit in the Rat," <u>Anal N.Y. Academy of Sciences</u> , Fourth Colloquium in Biological Sciences: Blood-Brain Transfer, Jun. 14, 1988, Vol. 529, pp. 131-134.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	9	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B159 **	LIU et al., "S-Transnitrosation Reactions are Involved in the Metabolic Fate and Biological Actions of Nitric Oxide," <u>J. of Pharmacology and Experimental Therapeutics</u> , 1998, Vol. 284, No. 2, pp. 526-534, American Society for Pharmacology and Experimental Therapeutics, U.S.A.	
	B160	LOPEZ et al., "Novel Diazeniumdiolates Nitric Oxide Donors for Biomedical Applications," (#297.), <u>Abstracts of Papers</u> , Part 2, 224 th ACS National Meeting, Aug. 18-22, 2002, Boston, MA, American Chemical Society.	
	B161 **	MARLETTA et al., "Unraveling the Biological Significance of Nitric Oxide," <u>BioFactors</u> , 1990, Vol. 2, No. 4, pp. 219-225, Oxford University Press.	
	B162	MARXER et al., "Nitric Oxide Releasing Sol-Gel Materials: Toward Improved Subcutaneous Sensors," (#104.), <u>Abstracts of Papers</u> , Part 1, 222 nd ACS National Meeting, Aug. 26-30, 2001, Chicago, IL, American Chemical Society.	
	B163	MARXER et al., "Preparation of Nitric Oxide (NO)-Releasing Sol-Gels for Biomaterial Applications," <u>Chem. Mater.</u> , 2003, Vol. 15, No. 22, pp. 4193-4199, American Chemical Society.	
	B164	MARXER et al., "Sol-Gel Derived Nitric Oxide-Releasing Oxygen Sensors," <u>The Analyst</u> , 2005, Vol. 130, pp. 206-212, The Royal Society of Chemistry.	
	B165 **	McLAUGHLIN-BORLACE et al., "Bacterial Biofilm on Contact Lenses and Lens Storage Cases in Wearers with Microbial Keratitis," <u>J. of Applied Microbiology</u> , 1998, Vol. 84, pp. 827-838, The Society for Applied Microbiology.	
	B166 **	MERRIFIELD R., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <u>Synthesis of a Tetrapeptide</u> , July 20, 1963, Vol. 85, pp. 2149-2154.	
	B167 **	MEYER et al., "Kinetics and Equilibria of S-nitrosothiol-thiol Exchange Between Glutathione, Cysteine, Penicillamines and Serum Albumin," <u>FEBS Letters</u> , 1994, Vol. 345, pp. 177-180, Federation of European Biochemical Societies.	
	B168	MEYERHOFF et al., "Enhancing the Biocompatibility and In Vivo Performance of Intravascular Chemical Sensors Using Nitric Oxide Release Polymers," (#132.), <u>Abstracts of Papers</u> , Part 1, 218 th ACS National Meeting, Aug. 22-26, 1999, New Orleans, LA, American Chemical Society.	
	B169 **	MOHANRAJ et al., "Phase-Transfer-Catalyzed Chlorination of Poly(<i>p</i> -methylstyrene)," <u>Macromolecules</u> , 1986, Vol. 19, pp. 2470-2472, American Chemical Society.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Emst V. ARNOLD
Sheet	10	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B170 **	MONCADA et al., "Relationship Between Prostacyclin and Nitric Oxide in the Thrombotic Process," <u>Thrombosis Research Supplement XI</u> , 1990, pp. 3-13, Pergamon Press plc.	
	B171 **	MONCADA et al., "Nitric Oxide: Physiology, Pathophysiology, and Pharmacology," <u>Pharmacological Reviews</u> , 1991, Vol. 43, No. 2, pp. 109-142, The American Society for Pharmacology and Experimental therapeutics.	
	B172 **	MOORADIAN et al., "Nitric Oxide (NO) Donor Molecules: Effect of NO Release Rate on Vascular Smooth Muscle Cell Proliferation In Vitro," <u>J. Cardiovasc. Pharmacol.</u> , 1995, Vol. 25, No. 4, pp. 674-678, Raven Press, Ltd., NY	
	B173 **	MORLEY et al., "Mechanism of Vascular Relaxation Induced by the Nitric Oxide (NO)/Nucleophile Complexes, a New Class of NO-Based Vasocilators," <u>J. Cardiovasc. Pharmacol.</u> , 1993, Vol. 21, No. 4, pp. 670-676, Raven Press, Ltd, NY.	
	B174 **	MOWERY et al., "Preparation and Characterization of Hydrophobic Polymeric Films that are Thromboresistant Via Nitric Oxide Release," <u>Biomaterials</u> , 2000, Vol. 21, pp. 9-21, Elsevier Science Ltd.	
	B175	MOWERY et al., "More Biocompatible Electrochemical Sensors Through the Use of Combined Nitric Oxide Release/Ion Sensing Polymeric Films," (#339.), <u>Abstracts of Papers</u> , Part 2, 213 th ACS National Meeting, Apr. 13-17, 1997, San Francisco, CA, American Chemical Society.	
	B176	MOWERY et al., "Polymeric Diazeniumdiolates for Fabricating Thromboresistant Electrochemical Sensors Via Nitric Oxide Release," (#034.), <u>Abstracts of Papers</u> , Part 2, 216 th ACS National Meeting, Aug. 23-27, 1998, Boston, MA, American Chemical Society.	
	B177	NABLO et al., "In Vitro Cytotoxicity of Nitric Oxide-Releasing Sol-Gel Derived Materials," <u>Biomaterials</u> , 2005, Vol. 26, pp. 4405-4415, Elsevier Ltd.	
	B178	NABLO et al., "Nitric Oxide-Releasing Sol-Gels as Antibacterial Coatings for Orthopedic Implants," <u>Biomaterials</u> , 2005, Vol. 26, pp. 917-924, Elsevier Ltd.	
	B179 **	NABLO et al., "Sol-Gel Derived Nitric-Oxide Releasing Materials that Reduce Bacterial Adhesion," <u>J. Am. Chem. Soc.</u> , 2001, Vol. 123, No. 39, pp. 9712-9713, American Chemical Society.	
	B180 **	NEERGAARD L., "FDA Approves Stent that Emits Medication" <u>Milwaukee Journal Sentinel</u> , April 2003, 2 pages [retrieved online on 6/17/2007]. Retrieved from the Internet: <URL: http://findarticles.com/p/articles/mi_qn4196/is_20030425/ai_n10868900/print >.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: October 12, 2007 <i>(use as many sheets as necessary)</i>				Filing Date	01/06/2005
				First Named Inventor	Ernst V. ARNOLD
				Art Unit	1616
				Examiner Name	Unassigned
Sheet	11	of	15	Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	B181 **	OLIVER et al., "The Internal Calcium Concentration of Human Platelets Increases During Chilling," <i>Biochimica et Biophysica Acta</i> , 1999, Vol. 1416, pp. 349-360, Elsevier Science B.V.			
	B182 **	PALMER et al., "A Novel Citrulline-Forming Enzyme Implicated in the Formation of Nitric Oxide by Vascular Endothelial Cells," <i>Biochemical and Biophysical Research Communications</i> , Jan. 16, 1989, Vol. 158, No. 1, pp. 348-352, Academic Press, Inc.			
	B183 **	PARZUCHOWSKI et al., "Synthesis and Characterization of Polymethacrylate-Based Nitric Oxide Donors," <i>J. Am. Chem. Soc.</i> , 2002, Vol. 124, No. 41, pp. 12182-12191, American Chemical Society.			
	B184	PASSERINI, D., "The Design, Synthesis, and Characterization of Lung Specific Polyamine Diazeniumdiolates in the Treatment of Pulmonary Hypertension," <i>Dissertation Abstracts International</i> , Jan. 2000, Vol. 60, No. 7, pp. 3269-B (ISSN 0419-4217) (Order No. DA 9940593).			
	B185	RAO et al., "Poly(butanediol Spermate): A Hydrolytically Labile Polyester-Based Nitric Oxide Carrier," <i>J. Bioactive and Compatible Polymers</i> , Jan. 1999, Vol. 14, No. 1, pp. 54-63, Technomic Publishing Co. Inc.			
	B186 **	RAULLI R., "Inhibition of Human Platelet Aggregation by Diazeniumdiolates: Extent of Inhibition Correlates with Nitric Oxide Load Delivered," <i>J. Pharm. Pharmacol.</i> , 1998, Vol. 50, pp. 75-82.			
	B187	REYNOLDS et al., "Bis-diazeniumdiolates of Dialkyldiamines: Enhanced Nitric Oxide Loading of Parent Diamines," <i>Org. Lett.</i> , 2005, Vol. 7, No. 14, pp. 2813-2816, American Chemical Society.			
	B188	REYNOLDS et al., "Nitric Oxide Releasing Polyurethanes with Covalently Linked Diazeniumdiolated Secondary Amines," <i>Biomacromolecules</i> , 2006, Vol. 7, No. 3, pp. 987-994, American Chemical Society.			
	B189	SAAVEDRA et al., "Chemistry of the Diazeniumdiolates. O- versus N-Alkylation of the RNH[N(O)NO] ⁻ Ion," <i>J. Am. Chem. Soc.</i> , 2004, Vol. 126, No. 40, pp. 12880-12887, American Chemical Society.			
	B190	SAAVEDRA et al., "Conversion of a Polysaccharide to Nitric Oxide-Releasing Form. Dual-Mechanism Anticoagulant Activity of Diazeniumdiolated Heparin," <i>Bioorg. Med. Chem. Lett.</i> , 2000, Vol. 10, pp. 751-753, Elsevier Science Ltd.			
	B191	SAAVEDRA J., "Nitrogen-Based Diazeniumdiolates: Versatile Nitric Oxide-Releasing Compounds in Biomedical Research and Potential Clinical Applications," <i>J. Chem. Ed.</i> , Dec. 2002, Vol. 79, No. 12, pp. 1427-1434.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	12	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B192	SAAVEDRA et al., "Synthesis of Labile Diazeniumdiolate Prodrugs for Controlled Delivery of Nitric Oxide," (#113.), <u>Book of Abstracts</u> , ACS National Meeting, Mar. 26-30, 2000, San Francisco.	
	B193	SAGIV J., "Organized Monolayers by Adsorption. I. Formation and Structure of Oleophobic Mixed Monolayers on Solid Surfaces," <u>J. Am. Chem. Soc.</u> , Jan. 2, 1980, Vol. 102, No. 1. pp. 92-98, American Chemical Society.	
	B194	SCHMELTZER et al., "Optimized Synthesis of Salicylate-based Poly(anhydride-esters)," <u>Polymer Bulletin</u> , 2003, Vol. 49, pp. 441-448, Springer-Verlag.	
	B195	SCHMIDT et al., "Determination of Nitrite and Nitrate by the Griess Reaction," <u>Methods in Nitric Oxide Research</u> , 1996, pp. 491-497, John Wiley & Sons.	
	B196	SCHWARTZ et al., "Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group," <u>Circulation</u> (Journal of the American Heart Association), Oct. 1, 2002, pp. 1866-1873.	
	B197 ✕	SEKHAR et al., "Dimethyl Suberimidate as an Effective Crosslinker for Antibody-Enzyme Conjugation," <u>Preparative Biochemistry</u> , 1991, Vol. 21, No. 4, pp. 215-227, Marcel Dekker, Inc.	
	B198	SERHATKULU S., "Diazeniumdiolates of Chitosan Derivatives and Polyethyleneimine for Controlled Selective Delivery of Nitric Oxide," <u>Dissertation Abstracts International</u> , May 2000, Vol. 60, No. 11, pg. 5503-B (ISSN 0419-4217) (Order No. DA9951317)	
	B199	SHAMI et al., "Antitumor Activity of JS-K [O ²⁻ -(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O ²⁻ Aryl Diazeniumdiolates in Vitro and in Vivo," <u>J. Med. Chem.</u> , 2006, Vol. 49, No. 14, pp. 4356-4366, American Chemical Society.	
	B200 ✕	SHENG et al., "Selective Functionalization of Poly(4-methylstyrene)," <u>Macromolecules</u> , 1997, Vol. 30, No. 21, pp. 6451-6457, American Chemical Society.	
	B201	SHOWALTER et al., "Potential Prodrugs of Nitric Oxide-Releasing Proli/NO," (#237.), <u>Abstracts of Papers</u> , Part 2, 227 th ACS National Meeting, Mar. 28-Apr. 1, 2004, Anaheim, CA, American Chemical Society.	
	B202	SHOWALTER et al., "Synthesis and Chemistry of Diazeniumdiolate Anions from Hindered Amines," <u>Abstracts of Papers</u> , Part 2, 225 th ACS National Meeting, Mar. 23-27, 2003, New Orleans, LA, American Chemical Society	
	B203 ✕	SILBERZAN et al., "Silanation of Silica Surfaces. A New Method of Constructing Pure or Mixed Monolayers," <u>Langmuir</u> , 1991, Vol. 7, No. 8, pp. 1647-1651, American Chemical Society.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	13	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	B204	SIM et al., "Solid-Phase C-Acylation of Active Methylene Compounds," <u>Tetrahedron Lett.</u> , 1998, Vol. 39, pp. 2195-2198, Elsevier Science Ltd..			
	B205	SIMMONS M., "Transdermal Delivery of Nitric Oxide Via Diazeniumdiolates with Optimization and Penetration Enhancement Methods," <u>Dissertation Abstracts International</u> , July 1998, Vol. 59, No. 1, pg. 180-B (ISSN 0419-4217) (Order No. DA9821359).			
	B206	SMITH et al., "Transdermal Delivery of Nitric Oxide from Diazeniumdiolates," <u>J. Controlled Release</u> , 1998, Vol. 51, pp. 153-159, Elsevier Science B.V.			
	B207 xx	SNYDER E., "Activation During Preparation and Storage of Platelet Concentrates," <u>Transfusion</u> , 1992, Vol. 32, No. 6, pp. 500-502.			
	B208	SRINIVASAN et al., "Alkyltrichlorosilane-Based Self-Assembled Monolayer Films for Stiction Reduction in Silicon Micromachines," <u>J. Microelectromechanical Systems</u> , June 1998, Vol. 7, No. 2, pp. 252-260, a Joint IEEE/ASME Publication.			
	B209	STASKO et al., "Dendrimers as a Scaffold for Nitric Oxide Release," <u>J. Am. Chem. Soc.</u> , 2006, Vol. 128, No. 25, pp. 8265-8271, American Chemical Society.			
	B210	TIERNEY et al., "Prevention and Reversal of Experimental Posthemorrhagic Vasospasm by the Periadventitial Administration of Nitric Oxide from a Controlled-release Polymer," <u>Neurosurgery</u> , Oct. 2001, Vol. 49, No. 4, pp. 945-953.			
	B211 xx	TILLMAN et al., "Formation of Multilayers by Self-Assembly," <u>Langmuir</u> , 1989, Vol. 5, pp. 101-111, American Chemical Society.			
	B212 xx	TRAUBE von W., "Ueber Synthesen Stickstoffhaltiger Verbindungen mit Hülfe des Stickoxyds," pp. 81-128.			
	B213 xx	TRUJILLO et al., "Xanthine Oxidase-mediated Decomposition of S-Nitrosothiols," <u>J. Biological Chemistry</u> , Apr. 3, 1998, Vol. 273, No. 14, pp. 7828-7834, The American Society for Biochemistry and Molecular Biology, Inc.			
	B214	TUTUSAUS et al., "Kharasch Addition Catalysed by Half-Sandwich Ruthenium Complexes. Enhanced Activity of Ruthenacarboranes," <u>Tetrahedron Lett.</u> , 2003, Vol. 44, pp. 8421-8425, Elsevier Ltd.			
	B215 xx	ULMAN A., "Formation and Structure of Self-Assembled Monolayers," <u>Chem. Rev.</u> , 1996, Vol. 96, No. 4, pp. 1533-1554, American Chemical Society.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/588,718
Date Submitted: <u>October 12, 2007</u>				Filing Date	01/06/2005
(use as many sheets as necessary)				First Named Inventor	Ernst V. ARNOLD
Sheet	14	of	15	Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B216	VERMA et al., "Nitric Oxide-Eluting Polyurethanes - Vascular Grafts of the Future?," <u>N. Engl. J. Med.</u> , Aug. 18, 2005, Vol. 353, No. 7, pp. 730-731, Massachusetts Medical Society.	
	B217	WANG et al., "Chemistry of the Diazeniumdiolates: Z ⇌ E Isomerism," <u>J. Am. Chem. Soc.</u> , 2005, Vol. 127, No. 15, pp. 5388-5395, American Chemical Society.	
	B218 **	WASSERMAN et al., "Structure and Reactivity of Alkylsiloxane Monolayers Formed by Reaction of Alkyltrichlorosilanes on Silicon Substrates," <u>Langmuir</u> , 1989, Vol. 5, no. 4, pp. 1074-1087, American Chemical Society.	
	B219 **	WINK et al., "Chemical Biology of Nitric Oxide: Regulation and Protective and Toxic Mechanisms," <u>Current Topics in Cellular Regulation</u> , 1996, Vol. 34, pp. 159-187, Academic Press, Inc.	
	B220 **	WINK et al., "Nitric Oxide Protects Against Cellular Damage and Cytotoxicity from Reactive Oxygen Species," <u>Proc. Natl. Acad. Sci. USA</u> , Nov. 1993, Vol. 90, pp. 9813-9817.	
	B221	WINKLER T., "Synthese und Untersuchung der NO-Freisetzungskinetik in wässrigen Medien und unter dem Einfluss von Cytochrom P-450-imitierenden biomimetischen Systemen" (Dissertation), 2006, Hamburg, pp. 1-221.	
	B222 **	WINOKUR et al., "Mechanism of Shape Change in Chilled Human Platelets," <u>Blood</u> , Apr. 1, 1995, Vol. 85, No. 7, pp. 1796-1804, The American Society of Hematology.	
	B223 **	WOLKERS et al., "From Anhydrobiosis to Freeze-drying of Eukaryotic Cells," <u>Comparative Biochemistry and Physiology</u> , Part A, 2002, Vol. 131, pp. 535-543, Elsevier Science Inc.	
	B224	YANG et al., "Microstamping of a Biological Ligand Onto an Activated Polymer Surface," <u>Adv. Mater.</u> , 2000, Vol. 12, No. 6, pp. 413-417, Wiley-Vch Verlag GmbH.	
	B225 **	YOSHIDA et al., "Thin Sol-Gel-Derived Silica Coatings on Dental Pure Titanium Casting", Department of Fixed Prosthodontics, Nagasaki University School of Dentistry, Nagasaki, Japan and Materials Section, Technology Center of Nagasaki, Omura, Japan, 1999, pp. 778-785, John Wiley & Sons, Inc. (CCC 0021-9304/99/060778-08)	
	B226 **	ZAI et al., "Cell-Surface Protein Disulfide Isomerase Catalyzes Transnitrosation and Regulates Intracellular Transfer of Nitric Oxide," <u>J. Clinical Investigation</u> , Feb. 1999, Vol. 103, No. 3, pp. 393-399.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>October 12, 2007</u> (use as many sheets as necessary)				Complete if Known	
Sheet	15	of	15	Application Number	10/588,718
				Filing Date	01/06/2005
				First Named Inventor	Ernst V. ARNOLD
				Art Unit	1616
				Examiner Name	Unassigned
				Attorney Docket Number	065611-0119

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	B227	ZHANG et al., "Nitric Oxide-Releasing Fumed Silica Particles: Synthesis, Characterization, and Biomedical Application," <u>J. Am. Chem. Soc.</u> , 2003, Vol. 125, No. 17, pp. 5015-5024, American Chemical Society.		T ⁶
	B228	ZHANG et al., "Nitric Oxide Releasing Silicone Rubbers with Improved Blood Compatibility: Preparation, Characterization, and In Vivo Evaluation," <u>Biomaterials</u> , 2002, Vol. 23, pp. 1485-1494, Elsevier Science Ltd.		
	B229	ZHANG et al., "Novel Silicone Materials with Improved Thromboresistance Via Nitric Oxide Release," (#251.), <u>Abstracts of Papers</u> , Part 2, 221 st ACS National Meeting, Apr. 1-5, 2001, San Diego, CA, American Chemical Society.		
	B230	ZHANG et al., "Polymer Films or Coatings Embedded with Nitric Oxide Releasing Fumed Silica Particles," (#8.), <u>Abstracts of Papers</u> , Part 2, 222 nd ACS National Meeting, Aug. 26-30, 2001, Chicago, IL, American Chemical Society.		
	B231	ZHANG et al., "Potentially More Blood Compatible Polymers Using Nitric Oxide Release Fumed Silica Fillers," (#40.), <u>Abstracts of Papers</u> , Part 2, 220 th ACS National Meeting, Aug. 20-24, 2000, Washington, DC, American Chemical Society.		
	B232	ZHOU et al., "Polymethacrylate-Based Nitric Oxide Donors with Pendant N-Diazeniumdiolated Alkyldiamine Moieties: Synthesis, Characterization, and Preparation of Nitric Oxide Releasing Polymeric Coatings," <u>Biomacromolecules</u> , 2005, Vol. 6, No. 2, pp. 780-789, American Chemical Society.		
	B233	ZHOU et al., "Preparation and Characterization of Polymeric Coatings with Combined Nitric Oxide Release and Immobilized Active Heparin," <u>Biomaterials</u> , 2005, Vol. 26, pp. 6506-6517, Elsevier Ltd.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.